Related news from |
Thu, 28 Mar 2024 12:13:14 +0000 |
Insiders Are Dumping These 10 Healthcare Stocks
In this article, we will take a detailed look at Insiders Are Dumping These 10 Healthcare Stocks. For a quick overview of such stocks, read our article Insiders Are Dumping These 5 Healthcare Stocks. Healthcare-focused investors were nervous when 2024 started, since election years usually do not bode well for the healthcare industry amid policy-related uncertainties. But healthcare stocks […]
|
Sat, 23 Mar 2024 09:06:00 +0000 |
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
|
Thu, 21 Mar 2024 12:21:38 +0000 |
Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Exelixis' (NASDAQ:EXEL) stock is up by a considerable 16% over the past month. However, we decided to pay attention to...
|
Sun, 17 Mar 2024 12:50:16 +0000 |
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
|
Wed, 13 Mar 2024 15:30:14 +0000 |
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
|
Mon, 11 Mar 2024 14:36:00 +0000 |
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.
|
Fri, 08 Mar 2024 14:38:44 +0000 |
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Biotech Stocks with Huge Potential. Recent developments, technological as well as optimism related to interest rate reductions, have led to […]
|
Fri, 08 Mar 2024 13:15:00 +0000 |
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
|
Thu, 07 Mar 2024 16:31:04 +0000 |
Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
|
Thu, 07 Mar 2024 15:08:53 +0000 |
10 Mid-Cap Stocks with Insider Purchases
In this article, we will take a detailed look at the 10 Mid-Cap Stocks with Insider Purchases. For a quick overview of such stocks, read our article 5 Mid-Cap Stocks with Insider Purchases. Investors are yet again in a wait-and-see mode ahead of key jobs and inflation numbers, but the overall sentiment in the market is positive, helped […]
|
Wed, 06 Mar 2024 21:45:00 +0000 |
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. The right company can yield extravagant returns for the lucky or prudent investor. However, choosing the wrong ones can lead to losses just as significant as the potential wins. Therefore, due diligence is important. A company announcing that it is developing a cure for cancer, MS, Huntington’s, or H
|
Wed, 06 Mar 2024 16:40:15 +0000 |
EXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
|
Sat, 02 Mar 2024 10:06:00 +0000 |
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
|
Fri, 01 Mar 2024 14:15:09 +0000 |
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
|
Thu, 29 Feb 2024 19:57:04 +0000 |
Is Now The Time To Put Exelixis (NASDAQ:EXEL) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
|
Tue, 27 Feb 2024 21:05:00 +0000 |
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
ALAMEDA, Calif., February 27, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:
|
Tue, 27 Feb 2024 13:00:03 +0000 |
Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
A closer look at one of the leaders in the renal cell carcinoma market
|
Mon, 19 Feb 2024 13:00:00 +0000 |
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too.
|
Wed, 14 Feb 2024 11:00:00 +0000 |
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
|
Wed, 14 Feb 2024 06:47:12 +0000 |
Jim Simons Increases Stake in Exelixis Inc
Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently bolstered its investment in Exelixis Inc (NASDAQ:EXEL), a notable player in the biopharmaceutical industry. The transaction, which took place on December 19, 2023, saw the firm adding 398,800 shares to its holdings, reflecting a 2.62% change in the position size.
|